BAMF (Biomarker Amplification Filter) shows promise for early MS (multiple sclerosis) diagnostic:
This article was originally published in Clinica
Executive Summary
Eclipse Diagnostics, a subsidiary of Large Scale Biology (LSB), says that evidence shows that its BAMF technology (Biomarker Amplification Filter) could lead to early diagnosis of multiple sclerosis (MS) and other life-threatening diseases. In a presentation last week at the American Academy of Neurology Meeting, in San Francisco, California, researchers using the BAMF technology reported the presence of distinct proteomic signatures in blood serum from MS patients. According to Vacaville, California-based LSB, findings from the study, entitled, "A Blood Test to Diagnose Multiple Sclerosis: Use of MALDI/TOF and Serum Proteomic Pattern Analysis", provide "further confirmation that the BAMF technology will lead to early diagnosis of diseases such as multiple sclerosis and various cancers."
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.